Vizient, a healthcare performance improvement company, recently released its Drug Price Forecast Highlights biannual report that provides an estimate of the change in the cost of medicines for 2019.
Vizient, a healthcare performance improvement company, recently released its Drug Price Forecast Highlights biannual report that provides an estimate of the change in the cost of medicines for 2019.
The projected inflation rate, which is weighted by Vizient member purchases and covers all classes of trade with the exception of 340B purchases, is projected to be 4.92%. This is a slower rate of growth compared with previous Vizient forecasts, such as 7.61% that was projected for 2018.
Over the time period studied, the highest spending based on therapeutic classes was seen in disease-modifying antirheumatic agents (DMARDs) for the treatment of rheumatoid arthritis. This class includes key products such as adalimumab, etanercept, and infliximab; all products for which biosimilars have been developed and FDA-approved, however not all are available on the market today.
“Where we need competition the most is in 2 areas: one, [for] drugs that have never had competition; drugs that have been going on for decades without competition. The second area is of high cost drugs. Well, [adalimumab, etanercept, and infliximab] meet both criteria. They have a strong grip on the entire marketplace, and they’re really expensive. That’s what gets us so excited about biosimilars,” said Dan Kistner, PharmD, senior vice president of pharmacy solutions at Vizient in an interview with The Center for Biosimilars®.
In fact, in rheumatoid arthritis, specifically, the report projects an 8.57% increase in the cost of the top 5 branded products in 2019: infliximab, adalimumab, etanercept, abatacept, and certolizumab.
“When you look at the [rheumatoid arthritis] market today, the uptake of biosimilars is 3%. It’s just not good enough to make a dent,” said Kistner. When asked if he thought the recent release of the Biosimilar Action Plan would help increase the market share of biosimilars, he said, “Anything that’s going to help those products come to market faster or fight current hurdles that they have—whether that be with reimbursement or therapeutic uptake– we fully support it.”
Competition fuels everything, said Kistner. In looking to address the drug pricing problem in America that has garnered a lot of media attention as of late, Kistner said that the answer could lie in biosimilars creating more competition in the market. “We have a solution to lower drug pricing in this country on the drugs that are the top 10 [most expensive] drugs for the country: it’s biosimilars. We’ve got to do everything we can to make sure that we’re limiting any risk or speed bumps in the road in getting them to market.”
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.